• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.对一名接受免疫治疗的黑色素瘤患者的多处转移灶中不同肿瘤逃逸机制的鉴定。
Cancer Immunol Immunother. 2007 Jan;56(1):88-94. doi: 10.1007/s00262-006-0166-2. Epub 2006 Apr 19.
2
HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.转移性黑色素瘤中HLA I类分子的表达与自体疫苗接种期间的肿瘤发展相关。
Cancer Immunol Immunother. 2007 May;56(5):709-17. doi: 10.1007/s00262-006-0226-7. Epub 2006 Sep 8.
3
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.免疫治疗后进展和消退的转移性黑色素瘤病灶中HLA I类表达的分析。
Immunogenetics. 2008 Aug;60(8):439-47. doi: 10.1007/s00251-008-0303-5. Epub 2008 Jun 11.
4
Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.免疫逃避标志物与免疫治疗后晚期黑色素瘤患者临床结局的关系。
Cancer Immunol Res. 2014 Jun;2(6):538-46. doi: 10.1158/2326-6066.CIR-13-0097. Epub 2014 Mar 10.
5
Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient.从一名患者身上建立的三种细胞系中黑色素瘤相关抗原以及参与抗原加工和呈递的分子的差异表达
Melanoma Res. 2004 Dec;14(6):463-71. doi: 10.1097/00008390-200412000-00005.
6
Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.黑色素瘤长期存活者中T细胞反应的序贯免疫逃逸与转变
J Immunol. 2005 Jun 1;174(11):6863-71. doi: 10.4049/jimmunol.174.11.6863.
7
Genetic evolution of T-cell resistance in the course of melanoma progression.黑色素瘤进展过程中T细胞抗性的遗传进化。
Clin Cancer Res. 2014 Dec 15;20(24):6593-604. doi: 10.1158/1078-0432.CCR-14-0567. Epub 2014 Oct 7.
8
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.肿瘤细胞在转移性黑色素瘤发展过程中通过β2-微球蛋白缺失实现免疫逃逸。
Int J Cancer. 2014 Jan 1;134(1):102-13. doi: 10.1002/ijc.28338. Epub 2013 Jul 16.
9
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.淋巴内树突状细胞疫苗接种可诱导肿瘤抗原特异性、归巢至皮肤的T淋巴细胞。
Clin Cancer Res. 2006 Oct 1;12(19):5801-8. doi: 10.1158/1078-0432.CCR-05-2421.
10
Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.黑色素瘤细胞上HLA I类抗原表达完全丧失:连续突变事件的结果。
Int J Cancer. 2003 Mar 1;103(6):759-67. doi: 10.1002/ijc.10906.

引用本文的文献

1
Cancer Vaccines in the Immunotherapy Era: Promise and Potential.免疫治疗时代的癌症疫苗:前景与潜力
Vaccines (Basel). 2023 Nov 29;11(12):1783. doi: 10.3390/vaccines11121783.
2
Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma.免疫检查点阻断疗法在治疗肾透明细胞癌中的研究进展与展望,以 PD-1/PD-L1 为代表。
Oncol Res. 2023 May 24;31(3):255-270. doi: 10.32604/or.2023.027942. eCollection 2023.
3
Cell Proteomic Footprinting: Advances in the Quality of Cellular and Cell-Derived Cancer Vaccines.细胞蛋白质组学足迹分析:细胞源性癌症疫苗质量的进展
Pharmaceutics. 2023 Feb 16;15(2):661. doi: 10.3390/pharmaceutics15020661.
4
Aberrant regulation of CXCR4 in cancer via deviant microRNA-targeted interactions.异常的 CXCR4 调节通过异常的 microRNA 靶向相互作用发生在癌症中。
Epigenetics. 2022 Dec;17(13):2318-2331. doi: 10.1080/15592294.2022.2118947. Epub 2022 Sep 6.
5
Changing Landscape of Cancer Vaccines-Novel Proteomics Platform for New Antigen Compositions.癌症疫苗领域的变化——新型蛋白质组学平台用于新型抗原组成。
Int J Mol Sci. 2022 Apr 15;23(8):4401. doi: 10.3390/ijms23084401.
6
Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of Class I Alterations in Cancer.影响整条6号染色体的拷贝数中性杂合性缺失是癌症中I类改变的常见机制。
Cancers (Basel). 2021 Oct 9;13(20):5046. doi: 10.3390/cancers13205046.
7
Antigenic Essence: Upgrade of Cellular Cancer Vaccines.抗原本质:细胞癌疫苗的升级
Cancers (Basel). 2021 Feb 12;13(4):774. doi: 10.3390/cancers13040774.
8
Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy.癌症疫苗:癌症免疫疗法的下一个突破。
J Immunol Res. 2020 Nov 17;2020:5825401. doi: 10.1155/2020/5825401. eCollection 2020.
9
Current state of melanoma diagnosis and treatment.黑色素瘤的诊断与治疗现状。
Cancer Biol Ther. 2019;20(11):1366-1379. doi: 10.1080/15384047.2019.1640032. Epub 2019 Aug 1.
10
Understanding heterogeneous tumor microenvironment in metastatic melanoma.解析转移性黑色素瘤异质性肿瘤微环境。
PLoS One. 2019 Jun 5;14(6):e0216485. doi: 10.1371/journal.pone.0216485. eCollection 2019.

本文引用的文献

1
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.在肿瘤逃避免疫监视过程中,转化生长因子-β直接作用于细胞毒性T细胞功能。
Cancer Cell. 2005 Nov;8(5):369-80. doi: 10.1016/j.ccr.2005.10.012.
2
Selective evolutionary pressure from the tissue microenvironment drives tumor progression.来自组织微环境的选择性进化压力驱动肿瘤进展。
Semin Cancer Biol. 2005 Dec;15(6):451-9. doi: 10.1016/j.semcancer.2005.06.002.
3
Immunosuppressive networks in the tumour environment and their therapeutic relevance.肿瘤环境中的免疫抑制网络及其治疗意义。
Nat Rev Cancer. 2005 Apr;5(4):263-74. doi: 10.1038/nrc1586.
4
Tumor-host immune interactions and dendritic cell dysfunction.肿瘤-宿主免疫相互作用与树突状细胞功能障碍。
Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7.
5
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.转化生长因子β1分泌升高和自然杀伤细胞2D(NKG2D)下调是癌症患者自然杀伤细胞(NK)细胞毒性受损的基础。
J Immunol. 2004 Jun 15;172(12):7335-40. doi: 10.4049/jimmunol.172.12.7335.
6
Control of autoimmunity by naturally arising regulatory CD4+ T cells.天然产生的调节性CD4 + T细胞对自身免疫的控制。
Adv Immunol. 2003;81:331-71. doi: 10.1016/s0065-2776(03)81008-8.
7
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.肿瘤细胞中Stat-3信号传导对先天性和适应性免疫反应的调节。
Nat Med. 2004 Jan;10(1):48-54. doi: 10.1038/nm976. Epub 2003 Dec 21.
8
CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells.侵袭性滋养层细胞表达的CXCL12可诱导CD16 - 人类自然杀伤细胞的特异性迁移。
Blood. 2003 Sep 1;102(5):1569-77. doi: 10.1182/blood-2003-02-0517. Epub 2003 May 1.
9
Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.结直肠癌肿瘤中MHC I类分子的完全缺失可由两种分子途径来解释:微卫星高度不稳定(MSI)阳性肿瘤中的β2-微球蛋白失活,以及MSI阴性肿瘤中的LMP7/TAP2下调。
Tissue Antigens. 2003 Mar;61(3):211-9. doi: 10.1034/j.1399-0039.2003.00020.x.
10
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.转化生长因子β1抑制NKp30和NKG2D受体的表达:对自然杀伤细胞介导的树突状细胞杀伤作用的影响。
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4120-5. doi: 10.1073/pnas.0730640100. Epub 2003 Mar 19.

对一名接受免疫治疗的黑色素瘤患者的多处转移灶中不同肿瘤逃逸机制的鉴定。

Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.

作者信息

Méndez Rosa, Ruiz-Cabello Francisco, Rodríguez Teresa, Del Campo Ana, Paschen Annette, Schadendorf Dirk, Garrido Federico

机构信息

Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nueves, Avda Fuerzas Armadas s/n, 18014, Granada, Spain.

出版信息

Cancer Immunol Immunother. 2007 Jan;56(1):88-94. doi: 10.1007/s00262-006-0166-2. Epub 2006 Apr 19.

DOI:10.1007/s00262-006-0166-2
PMID:16622680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11029888/
Abstract

The cytotoxic activity of T cells selects the outgrowth of tumor cells that escape from immune surveillance by different strategies. The different mechanisms that interfere with immune recognition and limit vaccination efficiency are still poorly understood. We analysed six cell lines established from different metastases of melanoma patient UKRV-Mel-20 for specific characteristics known to have an impact on the tumor-T cell interaction: (1) alterations in the HLA class I phenotype, (2) expression of Fas/CD95, and (3) expression of specific cytokines and chemokines. One of the cell lines, UKRV-Mel-20f, exhibited an HLA class I haplotype loss and just this cell line was also characterised by the expression of Fas/CD95 and of relatively high levels of proinflammatory chemokines suggesting that the cytotoxic activity of tumor-infiltrating T cells might have selected the outgrowth of this tumor cell variant. All other cell lines analysed showed no alterations in HLA class I expression, but, in contrast to UKRV-Mel-20f, expressed much lower levels of Fas/CD95 and of proinflammatory chemokines and some of them produced high levels of immunosuppressive TGF-beta1. These results suggest that in patient UKRV-Mel-20, tumor cells interfere with T cell recognition by different strategies which might partially explain why this patient did not have a clinical response to an autologous tumor cell vaccine.

摘要

T细胞的细胞毒性活性会选择那些通过不同策略逃避免疫监视的肿瘤细胞生长。不同的干扰免疫识别并限制疫苗接种效率的机制仍未得到充分理解。我们分析了从黑色素瘤患者Ukrv-Mel-20的不同转移灶建立的六个细胞系,以确定已知对肿瘤-T细胞相互作用有影响的特定特征:(1)HLA I类表型的改变,(2)Fas/CD95的表达,以及(3)特定细胞因子和趋化因子的表达。其中一个细胞系Ukrv-Mel-20f表现出HLA I类单倍型缺失,而恰恰是这个细胞系还具有Fas/CD95表达以及相对高水平的促炎趋化因子表达的特征,这表明肿瘤浸润T细胞的细胞毒性活性可能选择了这种肿瘤细胞变体的生长。分析的所有其他细胞系在HLA I类表达上均未显示改变,但与Ukrv-Mel-20f相反,它们表达的Fas/CD95和促炎趋化因子水平要低得多,并且其中一些产生高水平的免疫抑制性TGF-β1。这些结果表明,在患者Ukrv-Mel-20中,肿瘤细胞通过不同策略干扰T细胞识别,这可能部分解释了为什么该患者对自体肿瘤细胞疫苗没有临床反应。